Virtual IBD Clinic: Diagnosis and Medical Treatment

Virtual IBD Clinic: Diagnosis and Medical Treatment

Virtual IBD Clinic: Diagnosis and Medical Treatment

Explore the diagnosis and treatment of a young patient who presents with symptoms that are consistent with inflammatory bowel diseases (IBD).

  • Overview

    Please note:This activity is no longer available for continuing education credit.

    The management of IBD remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this program, Dr. Anita Afzali presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.

  • Faculty

    ReachMD Healthcare Image

    Anita Afzali, MD, MPH, FACG
    Medical Director
    OSU Inflammatory Bowel Disease Center
    The Ohio State University Wexner Medical Center
    Columbus, OH

  • Target Audience

    The target audience for this activity is primary care physicians, gastroenterologists, nurse practitioners, and physician assistants.

  • Learning Objectives

    After engaging in this activity, learners will be able to:

    • Describe indications for and interpretation of diagnostic testing in inflammatory bowel diseases (IBD)
    • Apply principles of IBD therapeutic management according to clinical symptoms, duration, and severity of disease 
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Postgraduate Institute for Medicine, the Crohn’s & Colitis Foundation, and RMEI Medical Education, LLC.

    ReachMD Healthcare ImageReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This activity is supported by educational grants from AbbVie Inc., Celgene Corporation, a Bristol Myers Squibb company, and Takeda Pharmaceuticals U.S.A., Inc.

  • Disclosure of Conflicts of Interest

    The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. 

  • Disclosure Declarations

    Anita Afzali, MD, MPH, FACG, has affiliations with AbbVie, Celgene, Janssen, Takeda (Consulting Fees); AbbVie, Janssen, Pfizer, Takeda (Speaker’s Bureau); AbbVie, BMS, Janssen, Takeda (Contracted Research).

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Crohn’s & Colitis Foundation planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Media


Facebook Comments


We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free